- BriaCell Therapeutics Corp. (BCT) has received an issue notification from the United States Patent and Trademark Office
- The issue notification is for the composition of matter and method of use of its personalized off-the-shelf cell-based immunotherapy for cancer
- The patent will issue on January 24, 2023, as US Patent No. 11,559,574, with the term extending to May 25, 2040
- The company was also awarded an Australian patent covering the composition of matter and method of use for its cancer immunotherapy technology in Australia
- BriaCell Therapeutics Corp. is an immuno-oncology-focused biotechnology company developing targeted approaches for the management of cancer
- BriaCell Therapeutics Corp. was up 2.165 per cent, trading at $7.55 at 9:45 AM ET
BriaCell Therapeutics Corp. (BCT) has received an issue notification from the United States Patent and Trademark Office.
The issue notification is for the composition of matter and method of use of its personalized off-the-shelf cell-based immunotherapy for cancer.
The patent will issue on January 24, 2023, as US Patent No. 11,559,574, with the term extending to May 25, 2040.
Furthermore, the company was awarded an Australian patent (Patent No. 2017224232, extends to February 27, 2037) covering the composition of matter and method of use for its whole-cell cancer immunotherapy technology in Australia.
“This is particularly important because the patent protection is not for one single type of cancer, but rather applies to multiple cancer indications,” stated Dr. William V. Williams, BriaCell’s President and CEO.
“Unlike other personalized treatments in the marketplace and under development, our pre-made personalized cancer immunotherapies would allow more rapid treatments and may significantly extend the lives of late-stage cancer patients,” he added.
US Patent No. 11,559,574, titled “Whole-cell cancer vaccines and methods for selection thereof,” covers the composition of matter and method of use of BriaCell’s personalized off-the-shelf whole-cell immunotherapies.
Once issued, the patent will provide intellectual property protection through May 25, 2040. A patent term extension under Hatch-Waxman potentially applies (which would extend such protection for an additional five years).
Also, BriaCell was awarded Australian Patent No. 2017224232, titled “Whole-cell cancer vaccines and methods for selection thereof,” for claims covering the composition of matter and method of use for BriaCell’s whole-cell immunotherapy for cancer in Australia.
BriaCell currently holds multiple issued patents and pending patent applications to cover its whole-cell immunotherapy’s composition of matter and method of use worldwide.
BriaCell has also added Carle Cancer Institute, Urbana, Illinois, and the American Oncology Network, LLC (AON), Baltimore, Maryland, as two additional clinical sites for the screening and enrollment of advanced breast cancer patients in the randomized Phase II study of BriaCell’s lead candidate, Bria-IMT, with Incyte’s PD-1 inhibitor, retifanlimab.
BriaCell Therapeutics Corp. is an immuno-oncology-focused biotechnology company developing targeted approaches for the management of cancer.
BriaCell Therapeutics Corp. was up 2.165 per cent, trading at $7.55 at 9:45 AM ET.
